An immunopharmacological approach for prevention of retrovirus-associated disease in human pathology.
Retroviruses of the HTLV and HIV subfamilies share a number of similar properties in terms of route of transmission and ultimate targeting to CD4+ T-cells, which results in leukaemic transformation in the case of HTLV and in depletion of CD4+ population and failure of T-helper function in HIV-infected individuals. Both diseases gain poor benefit from therapy at the stage of clinical diagnosis as ATL leukaemia or AIDS, respectively. Therefore the best chances to limit the worldwide distribution of these human retroviruses reside in an effective prevention of viral diffusion, possibly by vaccination, and of the onset of disease in virus-positive subjects. The possibility is discussed of defining protocols to prevent the development of clinical disease. These protocols could be based on pharmacological reconstitution of host's immune reactivity, that is altered early after infection with these retroviruses, and on the control of virus replication by antiviral therapy.